Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 44, Issue 2, Pages 451-458Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2013.2193
Keywords
HDAC inhibitor; large-cell lung cancer; anticancer activity; NCI-H460 cells line; nude mouse xenograft model; SAHA
Categories
Funding
- Natural Science Foundation of China [81172150]
- Fundamental Research Funds for the Central Universities of China
Ask authors/readers for more resources
Suberoylanilide hydroxamic acid (SAHA), a potent pan-histone deacetylase (HDAC) inhibitor, has been clinically approved for the treatment of cutaneous T-cell lymphoma (CTCL). SAHA has also been shown to exert a variety of anticancer activities in many other types of tumors, however, few studies have been reported in large-cell lung carcinoma (LCC). Our study aimed to investigate the potential antitumor effects of SAHA on LCC cells. Here, we report that SAHA was able to inhibit the proliferation of the LCC cell line NCI-H460 in a dose- and time-dependent manner, induced cell apoptosis and G(2)/M cell cycle arrest, decreased AKT and ERK phosphorylation, inhibited the expression of proangiogenic factors (VEGF, HIF-1 alpha) in vitro, and suppressed tumor progression in an NCI-H460 cell nude mouse xenograft model in vivo. These results indicate that SAHA can exert its strong antitumor effects in LCC patient.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available